Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-15

Clinical Trial Update: Relative Bioavailability and Food Effect Study of CVN424 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the relative bioavailability and food effect of CVN424 in Parkinson's disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CVN424 (CVN424)

Snippet

Sponsor: Cerevance Beta, Inc. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED | Results posted: 2024-08-15